Selenium for preventing cancer

Selenium is a trace element essential to humans. Higher selenium exposure and selenium supplements have been suggested to protect against several types of cancers. Two research questions were addressed in this review: What is the evidence for1. an aetiological relationship between selenium exposure...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cochrane database of systematic reviews 2011-05 (5), p.CD005195-CD005195
Hauptverfasser: Dennert, Gabriele, Zwahlen, Marcel, Brinkman, Maree, Vinceti, Marco, Zeegers, Maurice P A, Horneber, Markus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page CD005195
container_issue 5
container_start_page CD005195
container_title Cochrane database of systematic reviews
container_volume
creator Dennert, Gabriele
Zwahlen, Marcel
Brinkman, Maree
Vinceti, Marco
Zeegers, Maurice P A
Horneber, Markus
description Selenium is a trace element essential to humans. Higher selenium exposure and selenium supplements have been suggested to protect against several types of cancers. Two research questions were addressed in this review: What is the evidence for1. an aetiological relationship between selenium exposure and cancer risk in women and men?2. the efficacy of selenium supplementation for cancer prevention in women and men? We searched electronic databases and bibliographies of reviews and included publications. We included prospective observational studies to answer research question (a) and randomised controlled trials (RCTs) to answer research question (b). We conducted random effects meta-analyses of epidemiological data when five or more studies were retrieved for a specific outcome. We made a narrative summary of data from RCTs. We included 49 prospective observational studies and six RCTs. In epidemiologic data, we found a reduced cancer incidence (summary odds ratio (OR) 0.69 (95% confidence interval (CI) 0.53 to 0.91) and mortality (OR 0.55, 95% CI 0.36 to 0.83) with higher selenium exposure. Cancer risk was more pronouncedly reduced in men (incidence: OR 0.66, 95% CI 0.42 to 1.05) than in women (incidence: OR 0.90, 95% CI 0.45 to 1.77). These findings have potential limitations due to study design, quality and heterogeneity of the data, which complicated the interpretation of the summary statistics.The RCTs found no protective efficacy of selenium yeast supplementation against non-melanoma skin cancer or L-selenomethionine supplementation against prostate cancer. Study results for the prevention of liver cancer with selenium supplements were inconsistent and studies had an unclear risk of bias. The results of the Nutritional Prevention of Cancer Trial (NPCT) and SELECT raised concerns about possible harmful effects of selenium supplements. No reliable conclusions can be drawn regarding a causal relationship between low selenium exposure and an increased risk of cancer. Despite evidence for an inverse association between selenium exposure and the risk of some types of cancer, these results should be interpreted with care due to the potential limiting factors of heterogeneity and influences of unknown biases, confounding and effect modification.The effect of selenium supplementation from RCTs yielded inconsistent results. To date, there is no convincing evidence that selenium supplements can prevent cancer in men, women or children.
doi_str_mv 10.1002/14651858.CD005195.pub2
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3692366</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21563143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-503c9836aca88facb23f11e2c6f8036b1694a35e8595bb96f6fa65b74d84fab53</originalsourceid><addsrcrecordid>eNpVj81KAzEUhYMgtlZfYZgXmDE3N7kmG0GqVqHgQgV3Q5ImdWT-yLQF394Bf9DVWRzOx3cYy4CXwLm4AEkKtNLl8oZzBUaVw96JIzafClNIg68zdjqO75yjAdAnbCZAEYLEOcueQhO6et_msU_5kMIhdLu62-bedj6kM3YcbTOG8-9csJe72-flfbF-XD0sr9eFR6JdoTh6o5Gst1pH653ACBCEp6g5kgMy0qIKWhnlnKFI0ZJyl3KjZbRO4YJdfXEn8zZs_CSRbFMNqW5t-qh6W1f_m65-q7b9oUIyYlKYANlfwO_y5yl-Auh3Vho</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Selenium for preventing cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Dennert, Gabriele ; Zwahlen, Marcel ; Brinkman, Maree ; Vinceti, Marco ; Zeegers, Maurice P A ; Horneber, Markus</creator><creatorcontrib>Dennert, Gabriele ; Zwahlen, Marcel ; Brinkman, Maree ; Vinceti, Marco ; Zeegers, Maurice P A ; Horneber, Markus</creatorcontrib><description>Selenium is a trace element essential to humans. Higher selenium exposure and selenium supplements have been suggested to protect against several types of cancers. Two research questions were addressed in this review: What is the evidence for1. an aetiological relationship between selenium exposure and cancer risk in women and men?2. the efficacy of selenium supplementation for cancer prevention in women and men? We searched electronic databases and bibliographies of reviews and included publications. We included prospective observational studies to answer research question (a) and randomised controlled trials (RCTs) to answer research question (b). We conducted random effects meta-analyses of epidemiological data when five or more studies were retrieved for a specific outcome. We made a narrative summary of data from RCTs. We included 49 prospective observational studies and six RCTs. In epidemiologic data, we found a reduced cancer incidence (summary odds ratio (OR) 0.69 (95% confidence interval (CI) 0.53 to 0.91) and mortality (OR 0.55, 95% CI 0.36 to 0.83) with higher selenium exposure. Cancer risk was more pronouncedly reduced in men (incidence: OR 0.66, 95% CI 0.42 to 1.05) than in women (incidence: OR 0.90, 95% CI 0.45 to 1.77). These findings have potential limitations due to study design, quality and heterogeneity of the data, which complicated the interpretation of the summary statistics.The RCTs found no protective efficacy of selenium yeast supplementation against non-melanoma skin cancer or L-selenomethionine supplementation against prostate cancer. Study results for the prevention of liver cancer with selenium supplements were inconsistent and studies had an unclear risk of bias. The results of the Nutritional Prevention of Cancer Trial (NPCT) and SELECT raised concerns about possible harmful effects of selenium supplements. No reliable conclusions can be drawn regarding a causal relationship between low selenium exposure and an increased risk of cancer. Despite evidence for an inverse association between selenium exposure and the risk of some types of cancer, these results should be interpreted with care due to the potential limiting factors of heterogeneity and influences of unknown biases, confounding and effect modification.The effect of selenium supplementation from RCTs yielded inconsistent results. To date, there is no convincing evidence that selenium supplements can prevent cancer in men, women or children.</description><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD005195.pub2</identifier><identifier>PMID: 21563143</identifier><language>eng</language><publisher>England</publisher><subject>Case-Control Studies ; Female ; Humans ; Male ; Neoplasms - prevention &amp; control ; Odds Ratio ; Randomized Controlled Trials as Topic ; Selenium - administration &amp; dosage ; Selenium - adverse effects ; Sex Factors ; Trace Elements - administration &amp; dosage ; Trace Elements - adverse effects</subject><ispartof>Cochrane database of systematic reviews, 2011-05 (5), p.CD005195-CD005195</ispartof><rights>Copyright © 2011 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-503c9836aca88facb23f11e2c6f8036b1694a35e8595bb96f6fa65b74d84fab53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21563143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dennert, Gabriele</creatorcontrib><creatorcontrib>Zwahlen, Marcel</creatorcontrib><creatorcontrib>Brinkman, Maree</creatorcontrib><creatorcontrib>Vinceti, Marco</creatorcontrib><creatorcontrib>Zeegers, Maurice P A</creatorcontrib><creatorcontrib>Horneber, Markus</creatorcontrib><title>Selenium for preventing cancer</title><title>Cochrane database of systematic reviews</title><addtitle>Cochrane Database Syst Rev</addtitle><description>Selenium is a trace element essential to humans. Higher selenium exposure and selenium supplements have been suggested to protect against several types of cancers. Two research questions were addressed in this review: What is the evidence for1. an aetiological relationship between selenium exposure and cancer risk in women and men?2. the efficacy of selenium supplementation for cancer prevention in women and men? We searched electronic databases and bibliographies of reviews and included publications. We included prospective observational studies to answer research question (a) and randomised controlled trials (RCTs) to answer research question (b). We conducted random effects meta-analyses of epidemiological data when five or more studies were retrieved for a specific outcome. We made a narrative summary of data from RCTs. We included 49 prospective observational studies and six RCTs. In epidemiologic data, we found a reduced cancer incidence (summary odds ratio (OR) 0.69 (95% confidence interval (CI) 0.53 to 0.91) and mortality (OR 0.55, 95% CI 0.36 to 0.83) with higher selenium exposure. Cancer risk was more pronouncedly reduced in men (incidence: OR 0.66, 95% CI 0.42 to 1.05) than in women (incidence: OR 0.90, 95% CI 0.45 to 1.77). These findings have potential limitations due to study design, quality and heterogeneity of the data, which complicated the interpretation of the summary statistics.The RCTs found no protective efficacy of selenium yeast supplementation against non-melanoma skin cancer or L-selenomethionine supplementation against prostate cancer. Study results for the prevention of liver cancer with selenium supplements were inconsistent and studies had an unclear risk of bias. The results of the Nutritional Prevention of Cancer Trial (NPCT) and SELECT raised concerns about possible harmful effects of selenium supplements. No reliable conclusions can be drawn regarding a causal relationship between low selenium exposure and an increased risk of cancer. Despite evidence for an inverse association between selenium exposure and the risk of some types of cancer, these results should be interpreted with care due to the potential limiting factors of heterogeneity and influences of unknown biases, confounding and effect modification.The effect of selenium supplementation from RCTs yielded inconsistent results. To date, there is no convincing evidence that selenium supplements can prevent cancer in men, women or children.</description><subject>Case-Control Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasms - prevention &amp; control</subject><subject>Odds Ratio</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Selenium - administration &amp; dosage</subject><subject>Selenium - adverse effects</subject><subject>Sex Factors</subject><subject>Trace Elements - administration &amp; dosage</subject><subject>Trace Elements - adverse effects</subject><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVj81KAzEUhYMgtlZfYZgXmDE3N7kmG0GqVqHgQgV3Q5ImdWT-yLQF394Bf9DVWRzOx3cYy4CXwLm4AEkKtNLl8oZzBUaVw96JIzafClNIg68zdjqO75yjAdAnbCZAEYLEOcueQhO6et_msU_5kMIhdLu62-bedj6kM3YcbTOG8-9csJe72-flfbF-XD0sr9eFR6JdoTh6o5Gst1pH653ACBCEp6g5kgMy0qIKWhnlnKFI0ZJyl3KjZbRO4YJdfXEn8zZs_CSRbFMNqW5t-qh6W1f_m65-q7b9oUIyYlKYANlfwO_y5yl-Auh3Vho</recordid><startdate>20110511</startdate><enddate>20110511</enddate><creator>Dennert, Gabriele</creator><creator>Zwahlen, Marcel</creator><creator>Brinkman, Maree</creator><creator>Vinceti, Marco</creator><creator>Zeegers, Maurice P A</creator><creator>Horneber, Markus</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20110511</creationdate><title>Selenium for preventing cancer</title><author>Dennert, Gabriele ; Zwahlen, Marcel ; Brinkman, Maree ; Vinceti, Marco ; Zeegers, Maurice P A ; Horneber, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-503c9836aca88facb23f11e2c6f8036b1694a35e8595bb96f6fa65b74d84fab53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Case-Control Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasms - prevention &amp; control</topic><topic>Odds Ratio</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Selenium - administration &amp; dosage</topic><topic>Selenium - adverse effects</topic><topic>Sex Factors</topic><topic>Trace Elements - administration &amp; dosage</topic><topic>Trace Elements - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dennert, Gabriele</creatorcontrib><creatorcontrib>Zwahlen, Marcel</creatorcontrib><creatorcontrib>Brinkman, Maree</creatorcontrib><creatorcontrib>Vinceti, Marco</creatorcontrib><creatorcontrib>Zeegers, Maurice P A</creatorcontrib><creatorcontrib>Horneber, Markus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dennert, Gabriele</au><au>Zwahlen, Marcel</au><au>Brinkman, Maree</au><au>Vinceti, Marco</au><au>Zeegers, Maurice P A</au><au>Horneber, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selenium for preventing cancer</atitle><jtitle>Cochrane database of systematic reviews</jtitle><addtitle>Cochrane Database Syst Rev</addtitle><date>2011-05-11</date><risdate>2011</risdate><issue>5</issue><spage>CD005195</spage><epage>CD005195</epage><pages>CD005195-CD005195</pages><eissn>1469-493X</eissn><abstract>Selenium is a trace element essential to humans. Higher selenium exposure and selenium supplements have been suggested to protect against several types of cancers. Two research questions were addressed in this review: What is the evidence for1. an aetiological relationship between selenium exposure and cancer risk in women and men?2. the efficacy of selenium supplementation for cancer prevention in women and men? We searched electronic databases and bibliographies of reviews and included publications. We included prospective observational studies to answer research question (a) and randomised controlled trials (RCTs) to answer research question (b). We conducted random effects meta-analyses of epidemiological data when five or more studies were retrieved for a specific outcome. We made a narrative summary of data from RCTs. We included 49 prospective observational studies and six RCTs. In epidemiologic data, we found a reduced cancer incidence (summary odds ratio (OR) 0.69 (95% confidence interval (CI) 0.53 to 0.91) and mortality (OR 0.55, 95% CI 0.36 to 0.83) with higher selenium exposure. Cancer risk was more pronouncedly reduced in men (incidence: OR 0.66, 95% CI 0.42 to 1.05) than in women (incidence: OR 0.90, 95% CI 0.45 to 1.77). These findings have potential limitations due to study design, quality and heterogeneity of the data, which complicated the interpretation of the summary statistics.The RCTs found no protective efficacy of selenium yeast supplementation against non-melanoma skin cancer or L-selenomethionine supplementation against prostate cancer. Study results for the prevention of liver cancer with selenium supplements were inconsistent and studies had an unclear risk of bias. The results of the Nutritional Prevention of Cancer Trial (NPCT) and SELECT raised concerns about possible harmful effects of selenium supplements. No reliable conclusions can be drawn regarding a causal relationship between low selenium exposure and an increased risk of cancer. Despite evidence for an inverse association between selenium exposure and the risk of some types of cancer, these results should be interpreted with care due to the potential limiting factors of heterogeneity and influences of unknown biases, confounding and effect modification.The effect of selenium supplementation from RCTs yielded inconsistent results. To date, there is no convincing evidence that selenium supplements can prevent cancer in men, women or children.</abstract><cop>England</cop><pmid>21563143</pmid><doi>10.1002/14651858.CD005195.pub2</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1469-493X
ispartof Cochrane database of systematic reviews, 2011-05 (5), p.CD005195-CD005195
issn 1469-493X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3692366
source MEDLINE; Alma/SFX Local Collection
subjects Case-Control Studies
Female
Humans
Male
Neoplasms - prevention & control
Odds Ratio
Randomized Controlled Trials as Topic
Selenium - administration & dosage
Selenium - adverse effects
Sex Factors
Trace Elements - administration & dosage
Trace Elements - adverse effects
title Selenium for preventing cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A32%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selenium%20for%20preventing%20cancer&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Dennert,%20Gabriele&rft.date=2011-05-11&rft.issue=5&rft.spage=CD005195&rft.epage=CD005195&rft.pages=CD005195-CD005195&rft.eissn=1469-493X&rft_id=info:doi/10.1002/14651858.CD005195.pub2&rft_dat=%3Cpubmed%3E21563143%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21563143&rfr_iscdi=true